<DOC>
	<DOC>NCT01326481</DOC>
	<brief_summary>The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.</brief_summary>
	<brief_title>Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only) Histologically proven metastatic Her2negative breast cancer (Part 2 only) Measurable disease by RECIST 1.1 criteria (Part 2 only) Willing and able to consent for self to participate in study Progressive or recurrent disease after prior systemic chemotherapy regimen Age ≥ 18 years ECOG performance status of 0 or 1 Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or baseline (except alopecia) Adequate organ function Prior treatment with more than one systemic chemotherapy regimen for metastatic disease. Prior treatment with TRC105 History of hypersensitivity reaction to antimetabolite therapy Receipt of an investigational agent within 28 days of starting study treatment Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment Minor surgical procedures within 14 days prior to first dose of TRC105 History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months Uncontrolled chronic hypertension defined as systolic &gt; 140 or diastolic &gt; 90 despite optimal therapy Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105 Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month Hemorrhage within 28 days of starting study treatment Unhealed wounds within 28 days of starting study treatment History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness Known active viral or nonviral hepatitis History of hypersensitivity reaction to human or mouse antibody products Lung cancer with central chest lesions Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TRC105</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>CD105</keyword>
	<keyword>Endoglin</keyword>
	<keyword>TRACON Pharma</keyword>
	<keyword>Roswell Park Cancer Institute</keyword>
	<keyword>Department of Defense</keyword>
</DOC>